Abstract: Background. The determination of malignancy in follicular patterned thyroid lesions is based on postoperative histologic findings. Therefore, affected patients are referred for surgery, although only 20 % will have a final diagnosis of ma-lignancy. The aim of this study was to investigate the potential of galectin-3 as a marker of malignancy in these lesions. Methods. Fifty-four tissue specimens of follicular patterned thyroid lesions were immunohistochemically stained for galectin-3. Area and intensity scores were recorded. Results. Significant differences were found between the be-nign and malignant lesions. The sensitivity, specificity, positive predictive values, and negative predictive values of galectin-3 staining were 82%, ...
Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence o...
Introduction: Most of differentiated thyroid carcinomas should be easily revealed by fine-needle as...
The distinction between benign and malignant thyroid tumors is critical for the management of patien...
Background: Galectin-3 is an endogenous beta-galactoside binding lectin implicated in neoplastic tra...
The aim of this study was to investigate the usefulness of immunohistochemical expression galectin-3...
Objective: Malignant tumors of the thyroid gland exhibit a variety of histopathologies and clinical ...
Abstract: Background. Galectin-3 has been recently recog-nized as a promising presurgical marker of ...
BACKGROUND: In the USA, about 30 200 well-differentiated thyroid carcinomas were diagnosed in 2007, ...
Abstract: Background. Thyroid nodules are the most com-mon surgical disease of the thyroid. Fine-nee...
OBJECTIVE AND DESIGN: Galectin-3 is a beta-galactoside-binding protein that plays a role in cell adh...
BACKGROUND: In the USA, about 30 200 well-differentiated thyroid carcinomas were diagnosed in 2007,...
Background: non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), ...
Galectin-3 has been extensively studied as an immunohistochemical marker of thyroid malignancy, and ...
Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence o...
392-394The role of pro-angiogenic marker galectin-3 (GAL-3) was examined in differential diagnosis ...
Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence o...
Introduction: Most of differentiated thyroid carcinomas should be easily revealed by fine-needle as...
The distinction between benign and malignant thyroid tumors is critical for the management of patien...
Background: Galectin-3 is an endogenous beta-galactoside binding lectin implicated in neoplastic tra...
The aim of this study was to investigate the usefulness of immunohistochemical expression galectin-3...
Objective: Malignant tumors of the thyroid gland exhibit a variety of histopathologies and clinical ...
Abstract: Background. Galectin-3 has been recently recog-nized as a promising presurgical marker of ...
BACKGROUND: In the USA, about 30 200 well-differentiated thyroid carcinomas were diagnosed in 2007, ...
Abstract: Background. Thyroid nodules are the most com-mon surgical disease of the thyroid. Fine-nee...
OBJECTIVE AND DESIGN: Galectin-3 is a beta-galactoside-binding protein that plays a role in cell adh...
BACKGROUND: In the USA, about 30 200 well-differentiated thyroid carcinomas were diagnosed in 2007,...
Background: non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), ...
Galectin-3 has been extensively studied as an immunohistochemical marker of thyroid malignancy, and ...
Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence o...
392-394The role of pro-angiogenic marker galectin-3 (GAL-3) was examined in differential diagnosis ...
Thyroid cancer is not very common, accounting for 1-2% of all cancers, with a population incidence o...
Introduction: Most of differentiated thyroid carcinomas should be easily revealed by fine-needle as...
The distinction between benign and malignant thyroid tumors is critical for the management of patien...